Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Provencio, Mariano; Serna‐Blasco, Roberto; Nadal, Ernest; Insa, Amelia; García-Campelo, M.R.; Casal Rubio, J.; Dómine, Manuel; Majem, Margarita; Rodríguez‐Abreu, Delvys; Martínez‐Martí, Alex; de Castro, Javier; Cobo, Manuel; López-Vivanco, Guillermo; del Barco, E.; Bernabé Caro, Reyes; Viñolas, Núria; Barneto Aranda, Isidoro; Viteri, Santiago; Pereira, Eva; Royuela, Ana; Calvo, Virginia; Martín-López, Javier; Garcia‐García, Francisco; Casarrubios, Marta; Franco, Fernando; Sánchez‐Herrero, Estela; Massutí, Bartomeu; Cruz‐Bermúdez, Alberto; Romero, Atocha

doi:10.1200/jco.21.02660

Public

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Published in Journal of Clinical Oncology • May 16, 2022

Authors:

Mariano Provencio

Roberto Serna‐Blasco

Ernest Nadal

Abstract

PURPOSE: Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non-small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported. METHOD...

Subject

Medicine

Nivolumab

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!